Skip to main content
Clinical Trials/NCT04976751
NCT04976751UnknownPhase 1

Real World Study on the Application of Appropriate Electrophysiological Technology in the Diagnosis and Treatment of Andrology Diseases in Northwest China

Xijing Hospital1 site in 1 country274 target enrollmentStarted: May 13, 2021Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Sponsor
Enrollment
274
Locations
1
Primary Endpoint
National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI)

Study Overview

Brief Summary

To carry out real world research on the application of electrophysiology and other suitable technologies in the prevention and treatment of male diseases in medical institutions at all levels in Northwest China, and establish a database for the prevention and treatment of male diseases in Northwest China, so as to provide a basis for the formulation of guidelines or consensus on the application of electrophysiology for the prevention and treatment of male diseases in China.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient meets the diagnostic criteria of National Institutes of Health (NIH)Ⅲ type prostatitis;
  • NIH-CPSI score > 10;
  • The symptoms lasted for more than 3 months and failed to respond to drug treatment for more than 1 month;
  • Age ≥18 years old and ≤60 years old agrees and signs the informed consent;
  • Those who did not receive other similar treatment regimens during treatment.

Exclusion Criteria

  • All kinds of bacterial infection caused by acute or chronic orchitis or epididymitis, acute or chronic prostatitis, lower urinary tract infection;
  • Benign prostatic hyperplasia, prostate cancer, neurogenic bladder, urethral malformation or stricture and severe neurosis;
  • For patients with local pain as the main manifestation, attention should be paid to the exclusion of other lesions in the lower abdomen, perineum, lsosacral sites, such as ureteral calculi, bladder calculi, inguinal hernia, pubis, varicocele, epididymitis, rectocolic diseases, lsodorsal myofascitis, etc.;
  • Complicated with heart, brain, liver and hematopoietic system and other serious primary diseases, local skin infection or skin lesions in the treatment site;
  • People who have metal implants in their bodies cannot cooperate, such as patients with mental illness.
  • People who are allergic to the treatment of electrical stimulation or allergic to a variety of drugs.

Arms & Interventions

Electrophysiological treatment group

Experimental

Two electrodes covered the two acupoints of Zhongliao and Huiyang, one electrode covered the three acupoints of Zhongji, Guanyuan and Qihai, and two skin paste electrodes covered the three acupoints of Sanyinjiao, and connected the electric stimulation therapy instrument for 30 minutes. The intensity was based on the patient's tolerance. 4 weeks before the course of treatment, the treatment was performed once a day, 3 times a week.In the last 4 weeks, 20 times were performed twice a week.Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.

Intervention: Percutaneous electrical nerve stimulation treatment (Drug)

Outcomes

Primary Outcomes

National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI)

Time Frame: through study completion, an average of 1 year

Improvement rate = \[(score before treatment - score at the end of treatment)/score before treatment\] ×100% The improvement rate ≥75% was considered to be significant.The improvement rate \< 75% and ≥50% were considered to be better. The improvement rate \< 50% and ≥25% were considered as average efficacy.The improvement rate \< 25% indicates poor efficacy.

Secondary Outcomes

  • international prostate symptom score (IPSS)(through study completion, an average of 1 year)

Investigators

Sponsor
Xijing Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Yuan Jianlin-1

professor

Xijing Hospital

Study Sites (1)

Loading locations...

Similar Trials

Real World Study on the Application of... | Clinical Trial